ArticleInternational journal of fertility & sterility2026
Efficacy of Stop GnRH-Agonist/Antagonist versus GnRH-Antagonist Protocols in
Article in International journal of fertility & sterility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder impacting fertility. Controlled ovarian stimulation (COS) is a crucial step during Materials and Methods: A pilot randomized controlled trial was conducted from March to December 2023 at ValiE-Asr Hospital, Tehran. Forty PCOS patients were randomized into two groups: stop GnRH-agonist/GnRH-antagonist (n=20) and conventional GnRH antagonist (n=20). Participants' demographics, hormonal profiles, and treatment outcomes were recorded. The primary outcome was the number of mature oocytes retrieved; secondary outcomes included the number of follicles >12 mm on human chorionic gonadotropin (hCG) administration day and ovarian hyperstimulation syndrome (OHSS) incidence. Data was analyzed using SPSS 21.0, employing t tests, Mann-Whitney tests, and Chi-square tests as appropriate. Results: Baseline characteristics were similar between groups. The conventional protocol group had significantly more 16-18 mm follicles but no differences in total oocytes retrieved, metaphase 1 and 2 oocytes, or degenerated oocytes. Stimulation duration was shorter in the conventional group. No significant differences were observed in OHSS incidence or total gonadotropin dose. Conclusion: The Stop GnRH-agonist/GnRH-antagonist protocol is a viable alternative for PCOS patients, offering comparable oocyte yields and safety profiles to the conventional GnRH antagonist protocol. Larger studies are needed to confirm these findings and evaluate long-term outcomes such as pregnancy and live birth rates (registration number: IRCT20180409039247N10).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.